Published on November 7, 2012 at 11:21 PM
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that interim results from the Phase 2b/3 GALAXY trial will be presented at the Chemotherapy Foundation Symposium in New York City on Friday, November 9 during the 11:45 a.m. session on new agents for lung cancer. Presenting this data at the conference will be Dr. Suresh Ramalingham, Professor, Hematology & Medical Oncology, and Director, Translational Thoracic Malignancies Program, of the Winship Cancer Institute of Emory University.
The GALAXY trial is a Phase 2b/3 program designed to compare single agent docetaxel versus docetaxel plus ganetespib, a potent and selective Hsp90 inhibitor, as second-line treatment of advanced non-small cell lung cancer. The presentation will review prior results highlighted at the 2012 Congress of the European Society for Medical Oncology (ESMO) last September.
Source: Synta Pharmaceuticals Corp.
0a8064b7-ab86-4797-9ab8-f044d70b9e33|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Breast Cancer, Cancer, Cell, Chemotherapy, Docetaxel, Hematology, Leukemia, Lung Cancer, Medi-Cal, Melanoma, Multiple Myeloma, Myeloid Leukemia, Myeloma, Non-Small Cell Lung Cancer, Oncology, Protein, Small Cell Lung Cancer, Translational